Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. (28th December 2022)

• Record Type: Journal Article
• Authors: Nguyen, James; Wellard, Cameron; Chung, Eliza; Cheah, Chan Y.; Dickinson, Michael; Doo, Nicole Wong; Keane, Colm; Talaulikar, Dipti; Berkahn, Leanne; Morgan, Susan; Hamad, Nada; Cochrane, Tara; Johnston, Anna M.; Forsyth, Cecily; Opat, Stephen; Barraclough, Allison; Mutsando, Howard; Ratnasingam, Sumita; Giri, Pratyush; Wood, Erica M.; McQuilten, Zoe K.; Hawkes, Eliza A.
• Is Part Of: European journal of haematology. Volume 110:Number 4(2023)
• Page Start: 386
• Page End: 395
• Publication Date: 2022-12-28
• Subjects: classical Hodgkin lymphoma -- clinical characteristics -- demographic -- treatment regimen; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13915
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Comprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been systematically collected and described. We report real‐world data of 498 eligible patients from the first 5 years of the Lymphoma and Related Diseases Registry (LaRDR), including baseline characteristics, histologic subtype, and treatment patterns in first‐line therapy. Patient demographics and distribution of histopathological subtypes of cHL are similar to reported international cohorts. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was the most common therapy for both early and advanced‐stage disease, and 48% of patients with the early‐stage disease received radiotherapy. Treatment patterns are consistent with international guidelines. In comorbid patients ≥60 years of age with advanced‐stage disease, there is greater variation in treatment. In patients with a recorded response, the objective response rate (ORR) was 96% in early‐stage disease, and 88% in advanced‐stage disease. Early progression‐free survival data suggest Australian patients with cHL have good outcomes, similar to other international studies.